{"title":"External Beam Radiotherapy for Malignant Central Airway Obstruction in a Remote Rural Patient: A Case Study.","authors":"Eoin Collins, Druva Mitra, Scott Carruthers","doi":"10.1159/000542104","DOIUrl":"https://doi.org/10.1159/000542104","url":null,"abstract":"<p><strong>Introduction: </strong>Malignant central airway obstruction (MCAO) is a challenging therapeutic scenario, caused by tumour burden which limits airflow within the large airways. Squamous cell carcinoma (SCC) of the lung accounts for 50% of MCAO seen in the setting of non-small cell lung cancer. Here, we present the challenging case of a 63-year-old Indigenous Australian Female rom a remote rural community with background history of metastatic SCC of presumed pulmonary origin, who presented with a 1-week history of dyspnoea, stridor, and hoarse voice.</p><p><strong>Case presentation: </strong>A CT chest and neck demonstrated a superior mediastinal mass compressing the trachea to a narrowest diameter of 3 mm. The patient was stabilised in her local health centre, then transferred to our tertiary care facility for further evaluation and management. This stenotic lesion was not amenable to bronchoscopic or surgical intervention but was instead treated successfully with a short course of external beam radiotherapy, to total dose of 25Gy delivered over 10 fractions. The patient had almost complete resolution of respiratory symptoms with no significant radiotherapy related toxicity.</p><p><strong>Conclusion: </strong>Here, we discuss a challenging case of MCAO in a remote rural Australian patient and demonstrate the utility of external beam radiotherapy in this setting. We also discuss aspects of cancer related healthcare disparities which exist for Indigenous Australians. In doing so, we wish to highlight the need for improved cancer healthcare for such communities.</p>","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"17 1","pages":"1301-1308"},"PeriodicalIF":0.7,"publicationDate":"2024-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11556858/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142615563","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
John Corbyn Cravero, Laith Wahab, Dirk T Wilson, Ali Alani, Arthur Bredeweg, Roberto Aguirre
{"title":"High-Grade Sarcoma of the Pulmonary Artery That Mimicked a Pulmonary Embolism in a 39-Year-Old Patient with Recurrent Miscarriages: A Case Report.","authors":"John Corbyn Cravero, Laith Wahab, Dirk T Wilson, Ali Alani, Arthur Bredeweg, Roberto Aguirre","doi":"10.1159/000542052","DOIUrl":"https://doi.org/10.1159/000542052","url":null,"abstract":"<p><strong>Introduction: </strong>Primary pulmonary artery sarcoma is a rare malignancy with a poor prognosis, undefined treatment guidelines, and is often mistaken for a pulmonary embolism (PE) based on similar clinical presentation and radiographic findings.</p><p><strong>Case presentation: </strong>We present a case of a 39-year-old female with a past medical history of recurrent miscarriages who presented with a chief complaint of dyspnea. Due to a history of recurrent miscarriages, a predisposing coagulopathic condition was suspected for a PE. A V/Q scan showed high probability for a PE with bilateral perfusion defects. Subsequent CT angiographic imaging of the chest was read as positive for a massive PE. The patient was transferred to the medical ICU for tPA administration but developed worsening hypoxic respiratory failure and was transferred to an outside hospital for expert surgical consultation and thrombectomy. Intraoperative reports during thrombectomy commented on a mass within the pulmonary artery. Subsequent pathology showed a high-grade sarcoma. The patient was started on adjuvant chemotherapy with doxorubicin, ifosfamide, and MESNA; however, due to multiple comorbidities, the patient ultimately succumbed to her illness.</p><p><strong>Conclusion: </strong>This case underscores the diagnostic difficulty in distinguishing pulmonary artery sarcomas from a PE, especially in the presence of other confounders and biases.</p>","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"17 1","pages":"1294-1300"},"PeriodicalIF":0.7,"publicationDate":"2024-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11556859/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142615569","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Different Patterns of Platelet Count Fluctuation in Response to Various Anticancer Chemotherapies among Patient with Bladder Cancer.","authors":"Ayako Watanabe, Yu Ogawa, Misa Saeki, Takuya Nagata, Masashi Morita, Kenji Momo","doi":"10.1159/000541679","DOIUrl":"https://doi.org/10.1159/000541679","url":null,"abstract":"<p><strong>Introduction: </strong>In general, platelet counts fluctuate in cancer patients receiving anticancer therapy. It may include thrombocytopenia caused by bone marrow suppression due to cytotoxic anticancer agents and thrombocytosis due to rebound during recovery. This should not be the case in the case of administration of immune checkpoint inhibitors, given their mechanism of action.</p><p><strong>Case presentation: </strong>However, we have experienced a case of thrombocytosis in a patient treated with an immune checkpoint inhibitor. We present a platelet count pattern in patient with bladder cancer underwent Gemcitabine and Cisplatin (GC) therapy and pembrolizumab monotherapy.</p><p><strong>Conclusion: </strong>This case underscores the need for a diverse perspective on platelet behavior in clinical settings.</p>","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"17 1","pages":"1277-1281"},"PeriodicalIF":0.7,"publicationDate":"2024-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11556855/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142615555","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Kristofoor E Leeuwenberg, Rob Ter Heine, Johanna M M Gijtenbeek, Michel M van den Heuvel
{"title":"Polyradiculitis as a Neurological Complication Associated with Adagrasib: A Case Report.","authors":"Kristofoor E Leeuwenberg, Rob Ter Heine, Johanna M M Gijtenbeek, Michel M van den Heuvel","doi":"10.1159/000541988","DOIUrl":"https://doi.org/10.1159/000541988","url":null,"abstract":"<p><strong>Introduction: </strong>Adagrasib is an upcoming anticancer treatment for KRAS G12C-mutated non-small-cell lung carcinoma, colorectal cancer and potentially other solid tumors harboring this mutation. It is generally well-tolerated and reports of neurological adverse events so far have been limited.</p><p><strong>Case presentation: </strong>We present to our best knowledge the first case of a 70-year-old woman who was admitted with polyradiculitis as a treatment-related complication of adagrasib. Symptoms resolved after treatment with prednisone and therapy interruption of adagrasib followed by a permanent dose reduction. After the dose reduction, there was an ongoing effective tumor response at follow-up, and serum concentrations of adagrasib remained within the therapeutic index.</p><p><strong>Conclusion: </strong>Through this case report, we aim to bring attention to the possibility of this side effect, as we believe it is important to be aware of it for future patients undergoing treatment with adagrasib.</p>","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"17 1","pages":"1289-1293"},"PeriodicalIF":0.7,"publicationDate":"2024-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11556857/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142635894","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Yan Xiao, Jinwei Wang, Kai Yang, Meiling Jiang, Bo Zhang
{"title":"SARS-CoV-2-Induced Remission of Chemotherapy Resistance B-Cell Non-Hodgkin Lymphoma: A Case Report.","authors":"Yan Xiao, Jinwei Wang, Kai Yang, Meiling Jiang, Bo Zhang","doi":"10.1159/000541964","DOIUrl":"https://doi.org/10.1159/000541964","url":null,"abstract":"<p><strong>Introduction: </strong>Investigation on virus-host interaction may provide new clues for antitumor immunotherapy.</p><p><strong>Case presentation: </strong>In this case report, we describe an unusual case of B-cell non-Hodgkin lymphoma in an aged woman who recovered following SARS-COV-2 infection. We discuss the case and suggest that virus induced cross-reactivity against tumor account for the remission.</p><p><strong>Conclusion: </strong>Mapping epitope characteristics on B cell non-Hodgkin lymphoma antigen and on SARS-COV-2 antigen may provide much needed information for antigen based antitumor immune therapy in the future.</p>","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"17 1","pages":"1273-1276"},"PeriodicalIF":0.7,"publicationDate":"2024-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11542925/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142603344","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Osteosarcoma Arising from Iliac Bone Lesions of Hereditary Multiple Osteochondromas: A Case Report.","authors":"Tadamasa Handa, Kunihiro Asanuma, Hiroto Yuasa, Tomoki Nakamura, Tomohito Hagi, Katsunori Uchida, Akihiro Sudo","doi":"10.1159/000541480","DOIUrl":"10.1159/000541480","url":null,"abstract":"<p><strong>Introduction: </strong>Osteochondromas are benign tumors that arise primarily in the metaphyseal region of long bones. The malignant transformation rate is estimated to be less than 1% and 1-3% in solitary and multiple osteochondromas, respectively. Transformation to osteosarcoma is very rare. Little information is available on treatment or outcome. A rare case of osteosarcoma arising from hereditary multiple osteochondromas of the right iliac bone is reported.</p><p><strong>Case presentation: </strong>A 66-year-old woman presented with recurrent right abdominal pain. Computed tomography (CT) showed a mass protruding into the pelvic cavity, 9 cm × 7 cm × 7 cm, with bone destruction and internal calcification in the right iliac bone. A CT-guided biopsy was performed, and the diagnosis was osteosarcoma. After one course of chemotherapy with doxorubicin and ifosfamide, extensive resection of the tumor was performed. The pathology showed proliferation of highly pleomorphic dysplastic cells with bone formation inside the tumor just below the osteochondroma tissue, which led to the diagnosis of osteosarcoma arising from the osteochondroma. Three years after surgery, there was no evidence of recurrence or metastasis, and the patient was able to walk unassisted.</p><p><strong>Conclusion: </strong>A case of osteosarcoma arising from an iliac lesion of hereditary multiple osteochondromas was described. Although no recurrence or metastasis has been observed 3 years after surgery, further follow-up is necessary due to the short time after surgery.</p>","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"17 1","pages":"1266-1272"},"PeriodicalIF":0.7,"publicationDate":"2024-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11527461/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142557261","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Sofía Ruffini Egea, Sara Elena Campos Ramírez, Natalia Pilar Pascual de la Fuente, María Luna Monreal Cepero, Fatima Mocha Campillo, Pablo Trincado Cobos, Antonio Antón Torres, Javier Martínez Trufero
{"title":"Delayed and Long-Lasting Response to 177Lu-DOTATATE in a Head and Neck Paraganglioma: Case Report and Literature Review.","authors":"Sofía Ruffini Egea, Sara Elena Campos Ramírez, Natalia Pilar Pascual de la Fuente, María Luna Monreal Cepero, Fatima Mocha Campillo, Pablo Trincado Cobos, Antonio Antón Torres, Javier Martínez Trufero","doi":"10.1159/000541359","DOIUrl":"10.1159/000541359","url":null,"abstract":"<p><strong>Introduction: </strong>Malignant paragangliomas (M-PGL) are a group of neuroendocrine tumors that originate from chromaffin cells. The most common location for PGL is the head and neck, which comprise 65-70% of all PGL, and the M-PGL accounts for 0.6% of all head and neck cancers. It is a rare tumor, with an incidence of 2-8 per million. Diagnosing PGL can be challenging, and treatment for metastatic disease is usually not curative.</p><p><strong>Case presentation: </strong>A 66-year-old woman was diagnosed with left cervical pain and laterocervical mass in March 2015. Octreotide scintigraphy showed intense uptake in the cervical mass, two pulmonary micronodules of 4-5 mm, and another lesion in the lumbar region (L3-L4). The final diagnosis was malignant nonsecretory PGL with adjacent tissue involvement and distant metastases. After three different treatments with minimal symptomatic improvement, 177Lu-DOTATATE was requested off-label. With a dose of 7,400 MBq until January 2018, the patient showed remarkable symptomatic pain improvement and a decrease in tumor size.</p><p><strong>Conclusion: </strong>We believe that our case report provides relevant information that can be considered in similar cases. First, the patient tripled the expected survival in such a clinical setting, and this benefit seems to rely on 177Lu-DOTATATE treatment. Second, we documented an early symptomatic response to this treatment but a long-term delayed volumetric radiographic response.</p>","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"17 1","pages":"1252-1257"},"PeriodicalIF":0.7,"publicationDate":"2024-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11524611/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142543935","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Purpura Fulminans from <i>Capnocytophaga canimorsus</i> in an Immunocompromised Host.","authors":"Indumathy Varadarajan, Natalie Pham, Karen Ballen","doi":"10.1159/000541338","DOIUrl":"https://doi.org/10.1159/000541338","url":null,"abstract":"<p><strong>Introduction: </strong>Purpura fulminans is a rare but fatal manifestation of <i>Capnocytophaga canimorsus</i> bacteremia that can present in immunocompromised hosts. This can have a profound impact on patients, including recipients of allogeneic hematopoietic stem cell transplant. Despite aggressive therapy, mortality can be as high as 60% and most patients require amputation of multiple extremities.</p><p><strong>Case presentation: </strong>We present a 31-year-old woman s/p myeloablative allogeneic transplant, presenting with purpura fulminans and septic shock. She had been on Immunosuppressive therapy with rituximab and tacrolimus. Despite aggressive antibiotic coverage and supportive therapy, although her shock was resuscitated, she had to undergo bilateral below-knee amputations.</p><p><strong>Discussion: </strong>We attempt to highlight the clinical presentation, pathophysiology and potential therapeutic options for immunocompromised patients presenting with septic shock from <i>C. canimorsus</i>. The importance of pre-transplant counselling on handling and adoption of new pets to prevent zoonotic infections is also discussed. Early recognition and initiation of antibiotics play a crucial role to reduce mortality in patients receiving HSCT.</p>","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"17 1","pages":"1246-1251"},"PeriodicalIF":0.7,"publicationDate":"2024-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11521502/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142543976","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Brendan Coyne, Sanjeev Saravanakumar, Franco Murillo-Chavez, Nivedita Kharkongor Chengappa, Rida Ihsan, Bilal A Chaudhry
{"title":"Colorectal Carcinoma and Gluteal Abscesses in the Background of a Gait Disturbance Presentation.","authors":"Brendan Coyne, Sanjeev Saravanakumar, Franco Murillo-Chavez, Nivedita Kharkongor Chengappa, Rida Ihsan, Bilal A Chaudhry","doi":"10.1159/000541693","DOIUrl":"10.1159/000541693","url":null,"abstract":"<p><strong>Introduction: </strong>Profuse diarrhea and abdominal discomfort are well-documented symptoms of patients with known colorectal cancer. It is much less common for these patients to present with a chief complaint of gait disturbance and rhabdomyolysis. We present a case of incidentally discovered colorectal carcinoma in a patient who was initially evaluated for progressive weakness and recurrent falls.</p><p><strong>Case presentation: </strong>A 51-year-old man was admitted to our department for management of rhabdomyolysis in the setting of progressive lower extremity weakness and mechanical falls. He developed abdominal discomfort and bowel changes during his admission, and after further investigation, he was found to have a rectal polyp positive for invasive adenocarcinoma, as well as multiple gluteal abscesses. Workup for metastasis, mutations, and oncogenic biomarkers was unremarkable.</p><p><strong>Conclusion: </strong>This case is a demonstration of a medically complex patient presentation compounded by multifactorial processes. Future providers may take note that an initial absence of classic gastrointestinal (GI) symptoms does not necessarily rule out underlying GI cancer. Instead, the initial presentation of colorectal adenocarcinoma may manifest with paraneoplastic versus incidental progressive proximal limb weakness prior to GI symptoms such as diarrhea. Additionally, our report demonstrates a case of possible paraneoplastic gluteal abscesses, which may have further contributed to the patient's gait disturbance. However, it is unclear as to whether our patient's various symptoms were directly linked to one another, or if they were incidental co-presentations.</p>","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"17 1","pages":"1239-1245"},"PeriodicalIF":0.7,"publicationDate":"2024-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11517711/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142521104","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Yumiko Miyazaki, Aina Yamaguchi, Hitomi Nanbu, Akiko Shinagawa, Mana Fukushima, Makoto Orisaka, Yoshio Yoshida
{"title":"Low-Grade Uterine Adenosarcoma with Overexpression of MDM2 and CDK4 by Immunohistochemistry: A Case Report and Literature Review.","authors":"Yumiko Miyazaki, Aina Yamaguchi, Hitomi Nanbu, Akiko Shinagawa, Mana Fukushima, Makoto Orisaka, Yoshio Yoshida","doi":"10.1159/000541823","DOIUrl":"10.1159/000541823","url":null,"abstract":"<p><strong>Introduction: </strong>Uterine adenosarcoma (UA) is a rare malignant mesenchymal neoplasm characterized by benign epithelial and malignant stromal components. Comprehensive genomic profiling has identified a high frequency of murine double-minute type 2 (MDM2) and cyclin-dependent kinase 4 (CDK4) amplification in UA. However, the significance of these genetic alterations in tumor biology remains poorly understood. This report presents a case of UA with immunohistochemically positive MDM2 and CDK4 expression.</p><p><strong>Case presentation: </strong>The patient was a 72-year-old woman with a history of genital bleeding. Magnetic resonance imaging revealed an 11 × 5 × 7 cm mass in the endometrial cavity, extending into the uterine cervix. Biopsy of the tumor showed no malignant findings. The patient underwent total abdominal hysterectomy and bilateral salpingo-oophorectomy. Microscopically, the tumor consisted of benign glandular epithelial components and low-grade sarcoma. The diagnosis was UA stage IA, pT1aNxM0. No sarcomatous overgrowth and no myometrial or lymphovascular invasions were observed. Immunohistochemistry confirmed MDM2 and CDK4 expression in the mesenchymal tissue. No recurrence was observed 12 months post-surgery.</p><p><strong>Conclusion: </strong>The pathological diagnosis of UA was based on histomorphological features. This study demonstrates that immunohistochemistry for MDM2 and CDK4 can help elucidate the molecular genetic features of UA. Further studies are needed to correlate the expression of these genes with the biological behavior of UA.</p>","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"17 1","pages":"1229-1238"},"PeriodicalIF":0.7,"publicationDate":"2024-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11509490/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142495753","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}